Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
Clinical trial NCT07277452 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07277452
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-10
- Primary completion
- 2028-12-10
- Enrollment
- 156
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.